About Us:
Today, Alzheimer’s disease is diagnosed too late, making it difficult to treat and to develop a cure for. At RetiSpec, we are developing a scanner that detects Alzheimer’s biological markers years before symptoms occur, so that clinicians could intervene with emerging therapeutics, and pharmaceutical companies could find suitable populations to participate in clinical trials.

The Alzheimer’s Problem:
Alzheimer’s disease is a slow, fatal disease of the brain for which today there is no known cure. Diagnosing Alzheimer’s early is crucial, as patients can attempt to treat symptoms in earlier stages with potentially better results. However, current practice of diagnosing Alzheimer’s, mainly PET brain imaging, is expensive and not accessible everywhere, leading to the fact that today we only go to confirm Alzheimer’s well after symptoms occur instead of screening early. This leads to two issues - difficulty treating patients in such an advanced stage, and difficulty developing treatment because it is a hard and lengthy task to locate suitable pre-symptomatic populations for trials.

The Technology:
RetiSpec is developing a non-invasive, non-radioactive, eye scanner to detect the presence of Alzheimer’s disease hallmark biomarkers in the human eye, as an extension to the central nervous system (the brain). Our proprietary system is based on converging cutting edge neuroscience research and NASA-grade Hyperspectral Imaging technology. Our technology allows for a quick, simple, and cost-effective identification of Alzheimer’s biomarkers years before the emergence of clinical symptoms. Our device is designed to be portable and require minimal training, so it can be utilized wherever Alzheimer’s is being diagnosed or cared for - thus facilitating early intervention with emerging therapeutics, digital patient management, and widespread pre-symptomatic screening.

The Commercial Opportunity:
Alzheimer’s burden on the healthcare ecosystem is massive and rising –
- The most expensive disease in America - $247 billion healthcare system and out-of-pocket costs for 2016 in the US and Canada
- Number of patients worldwide is expected to double to 75 million by 2030
- Delaying onset in just 5 years is estimated at $80 billion savings in the US

So there is a push for treatments, but finding a cure is difficult –
- 93 ongoing trials in Alzheimer’s disease drugs (as of April 2016)
- An estimated $400 million were spent by pharmaceutical companies on PET brain screenings for drug trial recruitment alone – recruitment is often the longest stage in Alzheimer’s drug development

RetiSpec is positioned to help both sides of this equation by
a. Helping clinicians to detect Alzheimer’s early for clinical intervention
b. Helping pharma companies to lower patient recruiting times and costs

We are currently completing the proof-of-concept stage for our system and are actively seeking partnerships and investors. Please contact us to learn more about what we do and our vision for the future.

RetiSpec is unlocking the value of proactive Alzheimer’s care - Join us!